Preclinical data and rationale exist for preventing the activation of FXI and FXII preserving the hemostatic activity of FXI in COVID-19, and several inhibitors of FXII and FXI are currently under investigation [158] representing a promising therapeutic target against COVID-19 patients with severe disease. Here, F11 is linked to COVID-19.